ELISA/assay

Microphthalmia Associated Transcription Factor (MITF) ELISA Kit

MBS2019067

48-Strip-Wells

565 USD

ELISA Kit

Microphthalmia Associated Transcription Factor (MITF) ELISA Kit

Microphthalmia Associated Transcription Factor (MITF)

WS2A; MI; bHLHe32; Homolog Of Mouse Microphthalmia; Class E basic helix-loop-helix protein 32

microphthalmia-associated transcription factor, partial; Microphthalmia-associated transcription factor; microphthalmia-associated transcription factor; microphthalmia-associated transcription factor; Class E basic helix-loop-helix protein 32; bHLHe32

MITF

MITF; MITF; MI; WS2; CMM8; WS2A; bHLHe32; BHLHE32; bHLHe32

MITF_HUMAN

Human

140

This assay has high sensitivity and excellent specificity for detection of Microphthalmia Associated Transcription Factor (MITF). No significant cross-reactivity or interference between Microphthalmia Associated Transcription Factor (MITF) and analogues was observed.

For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C upon receipt while the others should be at 4 degree C. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal. The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Samples: Tissue homogenates, Cell lysates and other biological fluids. Assay Type: Sandwich. Detection Range: 0.156-10ng/mL. Sensitivity: Typically less than 0.059ng/mL.

Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Microphthalmia Associated Transcription Factor (MITF) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Microphthalmia Associated Transcription Factor (MITF) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 . Intra-Assay: CV<10% . Inter-Assay: CV<12% . Assay Procedure Summary: 1. Prepare all reagents, samples and standards;. 2. Add 100uL standard or sample to each well. Incubate 2 hours at 37 degree C;. 3. Aspirate and add 100uL prepared Detection Reagent A. Incubate 1 hour at 37 degree C;. 4. Aspirate and wash 3 times;. 5. Add 100uL prepared Detection Reagent B. Incubate 30 minutes at 37 degree C;. 6. Aspirate and wash 5 times;. 7. Add 90uL Substrate Solution. Incubate 15-25 minutes at 37 degree C;. 8. Add 50uL Stop Solution. Read at 450nm immediately.

Principle of the Assay: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Microphthalmia Associated Transcription Factor (MITF). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Microphthalmia Associated Transcription Factor (MITF). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Microphthalmia Associated Transcription Factor (MITF), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm 10nm. The concentration of Microphthalmia Associated Transcription Factor (MITF) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

7684294

BAA95209.1

O75030

52,527 Da

IL6-mediated Signaling Events Pathway (137932); Kit Receptor Signaling Pathway (198826); Melanogenesis Pathway (83092); Melanogenesis Pathway (504); Melanoma Pathway (83114); Melanoma Pathway (526); Neural Crest Differentiation Pathway (672460); Osteoclast Differentiation Pathway (193147); Osteoclast Differentiation Pathway (193096); Pathways In Cancer (83105)

This gene encodes a transcription factor that contains both basic helix-loop-helix and leucine zipper structural features. It regulates the differentiation and development of melanocytes retinal pigment epithelium and is also responsible for pigment cell-specific transcription of the melanogenesis enzyme genes. Heterozygous mutations in the this gene cause auditory-pigmentary syndromes, such as Waardenburg syndrome type 2 and Tietz syndrome. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]

MITF: a transcription factor that contains both basic helix-loop-helix and leucine zipper structural features. Plays a critical role in the differentiation of various cell types including neural crest- derived melanocytes, mast cells, osteoclasts and optic cup-derived retinal pigment epithelium. Two isoforms are known: the M-isoform is expressed exclusively in melanocytes, while the A-isoform has a much broader range of expression. Mutations in MITF can lead to Waardenburg syndrome. Ten alternatively spliced isoforms have been described. Protein type: Transcription factor; Oncoprotein; DNA-binding. Chromosomal Location of Human Ortholog: 3p14.2-p14.1. Cellular Component: protein complex; nucleus. Molecular Function: protein dimerization activity; RNA polymerase II transcription factor activity, enhancer binding; protein binding; chromatin binding. Biological Process: transcription from RNA polymerase II promoter; cell fate commitment; camera-type eye development; positive regulation of transcription, DNA-dependent; osteoclast differentiation; negative regulation of transcription from RNA polymerase II promoter; bone remodeling; regulation of cell proliferation; regulation of osteoclast differentiation; regulation of transcription, DNA-dependent; melanocyte differentiation; positive regulation of transcription from RNA polymerase II promoter; protein complex assembly. Disease: Waardenburg Syndrome, Type 2a; Albinism, Ocular, With Sensorineural Deafness; Melanoma, Cutaneous Malignant, Susceptibility To, 8; Tietz Syndrome

48-Strip-Wells

565 USD

96-Strip-Wells

765

5x96-Strip-Wells

2975

10x96-Strip-Wells

5340